NCL1 not only had significant growth inhibitory properties in vitro (Fig. 1C), but it also attenuated tumor growth in vivo at extremely low concentration levels as compared to previous LSD1 inhibitors (Fig. 6A). Here, CAPN3 is linked to neoplasm.